Tag: clot

Pulmonary Embolism (PE)

1. Initial assessment

Consider PE in unexplained breathlessness, pleuritic chest pain, syncope, haemoptysis, tachycardia or hypoxia.

Assess ABCDE, observations and haemodynamic stability. Obtain ECG and CXR where appropriate; neither excludes PE.

Cardiac arrest, obstructive shock or persistent hypotension (SBP <90 mmHg or fall ≥40 mmHg for >15 minutes, not otherwise explained).

  • Immediate senior ED and critical care involvement.
  • Resuscitate, provide oxygen and avoid excessive IV fluids in RV failure.
  • Urgent CTPA if feasible; bedside echo if too unstable for transfer.
  • Consider IV unfractionated heparin and urgent reperfusion, including systemic thrombolysis.

Do not delay emergency treatment for Wells, PERC or D-dimer.


2. Stable patient – Diagnostic pathway

PERC – Very low clinical suspicion only

Use PERC only when clinical suspicion is low and an alternative diagnosis is feasible. (Pre-test probability must be <15%)

All eight must be negative:

PERC CriterionRequired finding
Age<50 years
Heart rate<100/min
SpO₂≥95% on room air
Unilateral leg swellingAbsent
HaemoptysisAbsent
Recent surgery or significant trauma requiring hospitalisationAbsent
Previous DVT/PEAbsent
Exogenous hormone useAbsent

All negative: PE may be excluded without further testing in an appropriately selected patient.

Any positive or ongoing suspicion: calculate Wells.

Two-level Wells score

Wells Clinical FeaturePoints
Clinical DVT signs (leg swelling and deep vein tenderness)3
Alternative diagnosis less likely than PE3
Heart rate >100/min1.5
Immobilisation >3 days or surgery within 4 weeks1.5
Previous DVT/PE1.5
Haemoptysis1
Active/recent malignancy (treatment within 6 months or palliative)1

Wells >4 – PE likely: CTPA. Do not use D-dimer to exclude PE. Give interim therapeutic anticoagulation if imaging cannot be performed immediately, unless contraindicated.

Wells ≤4 – PE unlikely: D-dimer using CHFT thresholds. If results cannot be obtained within 4 hours, offer interim therapeutic anticoagulation unless contraindicated.

D-dimer – DDU assay thresholds

AgeNegative if
<50 years<230 ng/L
≥50 years<5 × age in years (ng/L)

Examples: 50 years <250; 60 <300; 70 <350; 80 <400; 90 <450.

  • Below threshold: PE excluded in the appropriate clinical context.
  • At or above threshold: imaging required.

Use only the locally validated assay and reporting units.

Imaging: CTPA first line

  • If imaging is delayed, offer interim therapeutic anticoagulation unless contraindicated.
    • Heparin 80unit/kg OR treatment dose Tinzaparin – (Give Prior to Urgent CTPA)
  • Consider V/Q imaging if CTPA is unsuitable (e.g. selected patients with severe renal impairment or contrast allergy).
  • Consider U/S if evident DVT

For stable patients requiring investigation, calculate sPESI to assess potential suitability for SDEC.

sPESI criterionPoints
Age >80 years1
History of cancer1
Chronic heart failure or lung disease1
Heart rate ≥110/min1
SBP <100 mmHg1
SpO₂ <90%1
  • sPESI = 0 → Consider SDEC ensure referred and treated (mSDEC will contact patient with a time to attend)
  • sPESI ≥1 → Senior review, ED investigation or admission will be considered
  • If imaging is delayed, offer interim therapeutic anticoagulation unless contraindicated.

3. Risk Stritification

RiskFeaturesManagement
HighCardiac arrest, shock or persistent hypotensionCritical care, urgent reperfusion assessment
Intermediate-highStable BP, elevated clinical risk (PESI III–V or sPESI ≥1), RV dysfunction and positive troponinMonitored admission, anticoagulation, senior/critical care review
Intermediate-lowStable BP, increased clinical risk and/or RV injury markers without meeting intermediate-high criteriaAnticoagulation, reassessment and appropriate monitoring
LowStable, usually sPESI 0, no concerning RV injury markersConsider SDEC/ambulatory treatment

4. Confirmed PE – Treatment

Low/Intermediate Risk – Anticoagulation

  • Apixaban or rivaroxaban first-line for most suitable patients.
  • Alternative anticoagulation may be needed in pregnancy, severe renal impairment, contraindications or selected cancer-associated VTE.
  • Check FBC, renal function, LFTs and coagulation screen; do not delay necessary treatment solely while awaiting results.
  • Treat confirmed PE for at least 3 months, then reassess duration.

High Risk – Thrombolysis decision

High-risk PE with a pulse

Actilyse (alteplase) – UK licensed regimen

WeightIV bolusIV infusionTotal
≥65 kg10 mg over 1–2 min90 mg over 2 h100 mg
<65 kg10 mg over 1–2 minRemainder over 2 hMaximum 1.5 mg/kg

Example: 60 kg → 10 mg bolus + 80 mg infusion = 90 mg total.

PE-related cardiac arrest

  • Consider fibrinolysis when PE is the suspected or confirmed cause of arrest.
  • Alteplase 50 mg IV bolus a further 50 mg may be considered.
  • Consider continuing CPR for 60–90 minutes after thrombolysis in selected patients.
  • Consider ECPR or alternative reperfusion where available.

Contraindications and monitoring

Check for major bleeding risk, including active bleeding, previous intracranial haemorrhage, recent stroke, intracranial pathology, recent major surgery or trauma, and recent anticoagulant use.

  • Monitor haemodynamics, bleeding and neurological status.
  • Follow local guidance for UFH interruption/resumption. The Actilyse SmPC advises starting or resuming heparin when aPTT is less than twice the upper limit of normal.
  • Discuss catheter-directed or surgical reperfusion if thrombolysis is contraindicated or unsuccessful.

5. Special circumstances and disposition

  • Pregnancy: use a pregnancy-specific PE pathway; LMWH is generally preferred.
  • Renal impairment/contrast allergy: discuss alternative imaging and anticoagulation with radiology/specialists.
  • Negative CTPA with persistent suspicion: reassess and discuss further investigation.

Consider admission for haemodynamic instability, significant oxygen requirement, RV dysfunction/myocardial injury requiring monitoring, significant comorbidity or unsafe ambulatory management.

For SDEC discharge: ensure anticoagulation supply, written bleeding/VTE advice, safety-netting and appropriate follow-up.


References